| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| galantamine hydrobromide | Capsule, modified release | 20.512 mg | Current | Unavailable | Manufacturing | 12/07/2024 |
| haloperidol | Injection, solution | 5 mg/mL | Resolved | Available | Manufacturing | 12/07/2024 |
| pregabalin | Capsule, hard | 75 mg | Resolved | Available | Commercial Changes / Commercial viability | 12/07/2024 |
| pregabalin | Capsule, hard | 300 mg | Resolved | Available | Manufacturing | 12/07/2024 |
| emtricitabine~tenofovir disoproxil maleate | Tablet, film coated | 200 mg~300 mg | Current | Limited Availability | Manufacturing | 12/07/2024 |
| cinacalcet hydrochloride | Tablet, film coated | 66 mg | Current | Unavailable | Manufacturing | 12/07/2024 |
| cinacalcet hydrochloride | Tablet, film coated | 99 mg | Current | Unavailable | Manufacturing | 12/07/2024 |
| ezetimibe~simvastatin | Tablet | 10 mg~20 mg | Current | Unavailable | Manufacturing | 12/07/2024 |
| olmesartan medoxomil~amlodipine besilate | Tablet, film coated | 20 mg~6.935 mg | Current | Unavailable | Manufacturing | 12/07/2024 |
| mercaptopurine monohydrate | Tablet | 50 mg | Current | Limited Availability | Manufacturing | 12/07/2024 |
| gliclazide | Tablet, modified release | 30 mg | Resolved | Available | Manufacturing | 12/07/2024 |
| Adalimumab | Injection, solution | 40 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 12/07/2024 |
| Adalimumab | Injection, solution | 40 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 12/07/2024 |
| carbidopa monohydrate~levodopa | Tablet, modified release | 54 mg~200 mg | Resolved | Available | Manufacturing | 12/07/2024 |
| adrenaline (epinephrine) | Injection, solution | 300 microgram | Discontinued | Reduction in supply until supply is exhausted | Manufacturing | 12/07/2024 |
| adrenaline (epinephrine) | Injection, solution | 150 microgram | Discontinued | Reduction in supply until supply is exhausted | Manufacturing | 12/07/2024 |
| lacosamide | Tablet, film coated | 50 mg | Current | Unavailable | Manufacturing | 12/07/2024 |
| lacosamide | Tablet, film coated | 100 mg | Resolved | Available | Manufacturing | 12/07/2024 |
| prucalopride succinate | Tablet | 2.642 mg | Current | Unavailable | Manufacturing | 12/07/2024 |
| sitagliptin hydrochloride monohydrate | Tablet, film coated | 27.25 mg | Current | Unavailable | Manufacturing | 12/07/2024 |
| ezetimibe~rosuvastatin calcium | Tablet | 10 mg~10.4 mg | Resolved | Available | Manufacturing | 12/07/2024 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~20.8 mg | Resolved | Available | Manufacturing | 12/07/2024 |
| octreotide | Injection, solution | 50 microgram/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 12/07/2024 |
| octreotide | Injection, solution | 100 microgram/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 12/07/2024 |
| captopril | Tablet, uncoated | 25 mg | Current | Unavailable | Manufacturing | 12/07/2024 |
| idarubicin hydrochloride | Injection, solution | 1 mg/mL | Current | Limited Availability | Manufacturing | 12/07/2024 |
| tobramycin | Inhalation, conventional | 60 mg/mL | Current | Unavailable | Manufacturing | 12/07/2024 |
| carbamazepine | Tablet, uncoated | 200 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 12/07/2024 |
| carbamazepine | Tablet, uncoated | 100 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 12/07/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 54 mg | Current | Limited Availability | Manufacturing | 12/07/2024 |
| hydroxocobalamin chloride | Injection, solution | 1.027 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 11/07/2024 |
| varenicline tartrate~varenicline tartrate | Tablet, film coated | .85 mg~1.71 mg | Current | Unavailable | Manufacturing | 11/07/2024 |
| varenicline tartrate | Tablet, film coated | 1.71 mg | Current | Unavailable | Manufacturing | 11/07/2024 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 5 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 11/07/2024 |
| vecuronium bromide | Injection, powder for | 10 mg | Current | Limited Availability | Unexpected increase in consumer demand | 11/07/2024 |
| carmustine | Injection, powder for | 100 mg | Current | Unavailable | Manufacturing | 11/07/2024 |
| paclitaxel | Injection, concentrated | 300 mg | Current | Limited Availability | Manufacturing | 11/07/2024 |
| modafinil | Tablet, uncoated | 100 mg | Current | Limited Availability | Manufacturing | 11/07/2024 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Current | Emergency Supply Only | Manufacturing | 11/07/2024 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Current | Limited Availability | Manufacturing | 11/07/2024 |
| estradiol | Drug delivery system, transdermal | .39 mg | Current | Limited Availability | Manufacturing | 11/07/2024 |
| methotrexate | Tablet | 10 mg | Anticipated | Available | Manufacturing | 11/07/2024 |
| doxorubicin hydrochloride | Injection, concentrated | 2 mg/mL | Current | Unavailable | Manufacturing | 11/07/2024 |
| potassium clavulanate~amoxicillin trihydrate | Suspension, powder for | 7.45 mg/mL~28.7 mg/mL | Current | Limited Availability | Manufacturing | 10/07/2024 |
| ceftazidime pentahydrate | Injection, powder for | 1.164 g | Resolved | Available | Manufacturing | 10/07/2024 |
| midazolam | Injection, solution | 5 mg | Resolved | Available | Manufacturing | 10/07/2024 |
| diazoxide | Injection, solution | 15 mg/mL | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 10/07/2024 |
| prochlorperazine maleate | Tablet | 5 mg | Resolved | Available | Commercial Changes / Commercial viability | 10/07/2024 |
| propranolol hydrochloride | Tablet, film coated | 40 mg | Resolved | Available | Manufacturing | 10/07/2024 |
| oxytocin | Injection, solution | 10 IU/mL | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 10/07/2024 |
| betahistine dihydrochloride | Tablet, uncoated | 16 mg | Current | Unavailable | Manufacturing | 10/07/2024 |
| tadalafil | Tablet, film coated | 5 mg | Current | Limited Availability | Manufacturing | 10/07/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Limited Availability | Manufacturing | 10/07/2024 |
| betahistine dihydrochloride | Tablet, uncoated | 16 mg | Current | Unavailable | Manufacturing | 10/07/2024 |
| acarbose | Tablet | 100 mg | Current | Limited Availability | Manufacturing | 10/07/2024 |
| desvenlafaxine benzoate | Tablet, modified release | 73.16 mg | Current | Unavailable | Manufacturing | 10/07/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Unavailable | Unexpected increase in consumer demand | 10/07/2024 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, film coated | 41.363 mg~10 mg | Current | Unavailable | Manufacturing | 10/07/2024 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Current | Unavailable | Manufacturing | 10/07/2024 |
| estradiol | Drug delivery system, transdermal | 1.56 mg | Current | Limited Availability | Manufacturing | 10/07/2024 |
| rosuvastatin calcium | Tablet, film coated | 5.21 mg | Current | Unavailable | Manufacturing | 10/07/2024 |
| chloramphenicol | Eye Drops, solution | 5 mg/mL | Current | Unavailable | Manufacturing | 10/07/2024 |
| paracetamol | Tablet, modified release | 665 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 10/07/2024 |
| naproxen | Tablet, uncoated | 250 mg | Resolved | Available | Manufacturing | 10/07/2024 |
| medroxyprogesterone acetate | Injection, suspension | 150 mg/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 10/07/2024 |
| doxorubicin hydrochloride | Injection, concentrated | 2 mg/mL | Current | Limited Availability | Manufacturing | 10/07/2024 |
| norethisterone acetate~estradiol | Drug delivery system, transdermal | 2.7 mg~.62 mg | Current | Unavailable | Manufacturing | 10/07/2024 |
| calcium folinate | Injection | 324.1 mg | Anticipated | Available | Manufacturing | 9/07/2024 |
| pentetic acid | Injection, powder for | 5 mg | Resolved | Available | Manufacturing | 9/07/2024 |
| olanzapine | Tablet, film coated | 7.5 mg | Resolved | Available | Manufacturing | 9/07/2024 |
| methotrexate | Injection, solution | 2.5 mg/mL | Resolved | Available | Manufacturing | 9/07/2024 |
| metoprolol succinate | Tablet, modified release | 190 mg | Anticipated | Available | Manufacturing | 9/07/2024 |
| metoprolol succinate | Tablet, modified release | 95 mg | Anticipated | Available | Manufacturing | 9/07/2024 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Current | Unavailable | Manufacturing | 9/07/2024 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Manufacturing | 9/07/2024 |
| dexamethasone sodium phosphate | Injection, solution | 4.37 mg/mL | Current | Limited Availability | Manufacturing | 9/07/2024 |
| drospirenone~ethinylestradiol | Tablet | 3 mg~30 microgram | Anticipated | Available | Manufacturing | 9/07/2024 |
| rabeprazole sodium | Tablet, enteric coated | 20 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 9/07/2024 |
| zolmitriptan | Tablet, film coated | 2.5 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 9/07/2024 |
| Omalizumab | Injection, solution | 150 mg | Current | Unavailable | Manufacturing | 9/07/2024 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~5.198 mg | Current | Unavailable | Manufacturing | 9/07/2024 |
| quetiapine fumarate | Tablet, film coated | 28.78 mg | Resolved | Available | Manufacturing | 9/07/2024 |
| rizatriptan benzoate | Tablet, orally disintegrating | 14.53 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 9/07/2024 |
| rizatriptan benzoate | Tablet, orally disintegrating | 14.53 mg | Current | Unavailable | Manufacturing | 9/07/2024 |
| aciclovir sodium dihydrate | Injection, powder for | 628.8 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 9/07/2024 |
| aciclovir sodium dihydrate | Injection, powder for | 314.4 mg | Resolved | Available | Unexpected increase in consumer demand | 9/07/2024 |
| metformin hydrochloride | Tablet, film coated | 500 mg | Anticipated | Available | Manufacturing | 9/07/2024 |
| gliclazide | Tablet, modified release | 30 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 9/07/2024 |
| estradiol~estradiol~norethisterone acetate | Drug delivery system, transdermal | .62 mg~.78 mg~2.7 mg | Resolved | Available | Manufacturing | 9/07/2024 |
| Avalglucosidase alfa | Injection, powder for | 100 mg | Anticipated | Available | Manufacturing | 9/07/2024 |
| clindamycin phosphate | Injection, solution | 0 QS | Resolved | Available | Manufacturing | 9/07/2024 |
| doxycycline monohydrate | Tablet, uncoated | 104.1 mg | Current | Limited Availability | Manufacturing | 9/07/2024 |
| disulfiram | Tablet, effervescent | 200 mg | Resolved | Available | Manufacturing | 9/07/2024 |
| baclofen | Tablet | 10 mg | Anticipated | Available | Manufacturing | 9/07/2024 |
| metformin hydrochloride | Tablet, film coated | 500 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 9/07/2024 |
| metformin hydrochloride | Tablet, film coated | 1000 mg | Current | Unavailable | Manufacturing | 9/07/2024 |
| ganciclovir sodium | Injection, powder for | 543 mg | Resolved | Available | Manufacturing | 8/07/2024 |
| prazosin hydrochloride | Tablet, uncoated | 5.476 mg | Current | Unavailable | Unexpected increase in consumer demand | 8/07/2024 |
| methotrexate | Injection, solution | 50 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 8/07/2024 |
| human menopausal gonadotrophin | Injection, powder for | 600 IU | Current | Limited Availability | Manufacturing | 8/07/2024 |
| human menopausal gonadotrophin | Injection, powder for | 1200 IU | Current | Limited Availability | Manufacturing | 8/07/2024 |
| ropivacaine hydrochloride | Injection, solution | 7.5 mg/mL | Resolved | Available | Manufacturing | 8/07/2024 |
| rosuvastatin calcium~ezetimibe | Tablet~Tablet, film coated | 5.198 mg~10 mg | Current | Unavailable | Manufacturing | 8/07/2024 |
| duloxetine hydrochloride | Capsule, enteric | 67.32 mg | Resolved | Available | Unexpected increase in consumer demand | 8/07/2024 |
| dobutamine hydrochloride | Injection, solution | 14.01 mg/mL | Current | Unavailable | Manufacturing | 8/07/2024 |
| raltitrexed | Injection, powder for | 2 mg | Current | Limited Availability | Unexpected increase in consumer demand | 8/07/2024 |
| meropenem | Injection, powder for | 1 g | Discontinued | Unavailable | Commercial Changes / Commercial viability | 8/07/2024 |
| meropenem | Injection, powder for | 500 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 8/07/2024 |
| aciclovir | Injection, solution | 25 mg/mL | Resolved | Available | Manufacturing | 8/07/2024 |
2024年7月16日